key: cord-0791423-peu8mhck authors: Czumbel, L. M.; Kiss, S.; Farkas, N.; Mandel, I.; Hegyi, A. E.; Nagy, A. K.; Lohinai, Z.; Szakacs, Z.; Hegyi, P.; Steward, M. C.; Varga, G. title: Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis date: 2020-05-27 journal: nan DOI: 10.1101/2020.05.26.20112565 sha: 436eba972b937a9a8478024aa3c9f78371a696bb doc_id: 791423 cord_uid: peu8mhck Objectives: Our aim was to conduct a meta-analysis on the reliability and consistency of SARS-CoV-2 viral RNA detection in saliva specimens. Methods: We reported our meta-analysis according to the Cochrane Handbook. We searched the Cochrane Library, Embase, Pubmed, Scopus, Web of Science and clinical trial registries for eligible studies published between 1 January and 25 April 2020. The number of positive tests and total number of conducted tests were collected as raw data. The proportion of positive tests in the pooled data were calculated by score confidence interval estimation with the Freeman-Tukey transformation. Heterogeneity was assessed using the I2 measure and the Chi2 test. Results: The systematic search revealed 96 records after removal of duplicates. 26 records were included for qualitative analysis and 5 records for quantitative synthesis. We found 91% (95%CI = 80%-99%) sensitivity for saliva tests and 98% (95%CI 89%-100%) sensitivity for nasopharyngeal swab (NPS) tests in previously confirmed COVID-19 infected patients, with moderate heterogeneity among studies. Additionally, we identified 18 registered, ongoing clinical trials on saliva-based tests for detection of the virus. Conclusion: Saliva tests offer a promising alternative to NPS for COVID-19 diagnosis. However, further diagnostic accuracy studies are needed to improve their specificity and sensitivity. The reporting of our meta-analysis follows the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) (Moher, Shamseer, Clarke, Ghersi, Liberati, Petticrew, Shekelle, Stewart, & Group, 2015) . The PRISMA checklist for our work is available in the supporting information (Table S1 ). We registered our meta-analysis protocol in the OSF (Open Science Framework by Center for Open Science) registries on 23 April 2020 (https://osf.io/3ajy7). Deviation from the registered protocol: Studies eligible according to our inclusion criteria did not present sufficient raw data to complete 2x2 contingency tables. True positive, true negative, false positive and false negative values were not generally available, thus sensitivity and specificity could not be separately calculated. Instead, positive event rates were pooled for statistical analysis. Details of the analysis are described in section Summary measures and synthesis of results. We included records if they have met the following eligibility criteria: 1) records published in scientific journals or clinical trial registry; 2) patients diagnosed with COVID-19; 3) index test: saliva specimens with PCR diagnostics for detecting SARS-CoV-2; 4) reference standard (comparator test): NPS specimens with PCR diagnostics for detecting SARS-CoV-2; 5) records written in English or available in English translation. Exclusion criteria: 1) publications with no primary results such as reviews, guidelines and recommendations; 2) publications dated before 1 Januaryand after 25 April, 2020; 3) gray and black literature. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020 . . https://doi.org/10.1101 Search strategy A systematic search in English language filtering for records published after 1 January 2020 was performed in five different major electronic databases (Cochrane Library, Embase, PubMed, Scopus, Web of Science) and also in five clinical trial registers (ClinicalTrial.gov, EU Clinical Trials Register, NIPH Clinical Trial Search, ISRCTN Registry, ANZCTR Registry). The last update of our systematic search was performed on 25 April 2020. Cited and citing papers of the relevant studies were screened for further eligible studies. The following key words were applied to each database to identify eligible records: (COVID 19 We used EndNote X9.3.3 reference manger to organize records. After removal of duplicates, two authors (A.H. and I.M.) independently screened the records for eligibility based on the titles and abstracts. Papers included at this stage were further appraised by reading the full text. Disagreement between reviewers was resolved by consulting a third reviewer (L.M.C.). Using a preconstructed standardized data extraction form, two authors (A.H. and I.M.) independently collected data from the included records. From primary studies the following information was extracted (Table 1) : first author's name, year of publication, place of study, study All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020 . . https://doi.org/10.1101 type, population size, age, gender, method of diagnosis, type of PCR kit, outcome parameters: number of total, positive and negative saliva tests and number of total, positive and negative NPS test. From registered study protocols the following information was extracted and demonstrated in Table S2 : Clinical Trial ID, Recruiting Status, Study type, Number of Centers and Study Design, Location, Population, Intervention, Comparison, Primary Outcomes, Secondary outcomes. In case of disagreement during extractions a third author (L.M.C.) was also involved. We evaluated the potential for bias, quality of reporting and applicability of the studies using the QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies 2) (Whiting, Rutjes, Westwood, Mallett, Deeks, Reitsma, Leeflang, Sterne, & Bossuyt, 2011) , which is a tool widely used to assess studies of diagnostic accuracy. Our appraisal consisted of evaluating the risk of bias and applicability in four domains: 1) patient selection, 2) conduct and interpretation of index test and 3) reference standard, 4) flow and timing. We applied the following review question to judge their applicability to our investigation: Are saliva specimens reliable for detecting SARS-CoV-2 in COVID-19 patients confirmed by nasopharyngeal swab testing? We used the preconstructed form available on the QUADAS-2 web page of the University of Bristol (Bristol) . In the synthesis of quantitative data we included patient-based data from consecutive case series. Case reports from single participants were excluded. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020 . . https://doi.org/10.1101 The sensitivity of the saliva test in the patient-based pooled data was calculated using the methods recommended by the working group of the Cochrane Collaboration. Because some of the sensitivity values are close to or equal to 1, the score confidence interval estimation (Wilson, 1927) was applied with the Freeman-Tukey double arcsine transformation (Freeman & Tukey, 1950) . Due to the great variance in population size and methodologies, the random effect model by DerSimonian and Laird (DerSimonian & Laird, 1986) was used with 95% CI for random-effects meta-analysis. Heterogeneity was assessed using the I 2 measure and the 2 test, where p < 0.1 is taken to indicate significant heterogeneity. I 2 values of 25%, 50%, and 75% were identified as low, moderate, and high estimates respectively. (Higgins, Altman, Gøtzsche, Jüni, Moher, Oxman, Savović, Schulz, Weeks, & Sterne, 2011) . Statistical analyses were carried out using the STATA software version 15.0. We included 20 articles for full-text evaluation of completed studies. Out of these, 8 were included in the qualitative synthesis, from which 5 were also included in the quantitative synthesis. Figure 1 illustrates the study selection process. Our search in the clinical trial register yielded 19 protocols, out of which 1 was excluded due to different topic. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020 . . https://doi.org/10.1101 All five records included in the quantitative synthesis were consecutive case series, involving 123 patients from 5 distinct global locations (Table 1) (Azzi, Carcano, Gianfagna, Grossi, Gasperina, Genoni, Fasano, Sessa, Tettamanti, Carinci, Maurino, Agostino, Tagliabue, & Baj, 2020; Bae, Kim, Kim, Cha, Lim, Jung, Kim, Oh, Lee, Choi, Sung, Hong, Chung, & Kim, 2020; Fang, Zhang, Hang, Ai, Li, & Zhang, 2020; To, Tsang, Leung, Tam, Wu, Lung, Yip, Cai, Chan, Chik, Lau, Choi, Chen, Chan, Chan, Ip, Ng, Poon, Luo, Cheng, Chan, Hung, Chen, Chen, & Yuen, 2020; Williams, Bond, Zhang, Putland, & Williamson, 2020) . All publications included patients with confirmed diagnoses of COVID-19. No other restrictions on inclusion were stated in any of the studies. In the qualitative synthesis we also included another consecutive case series (Table 1) . But, in their work Wyllie et al. presented 38 matching NPS and saliva samples from 29 patients without identifying double or multiple samplings of individual patients. Therefore, their sample-wise results cannot be combined for quantitative analysis with the others which reported patient-wise data (Wyllie, Fournier, Casanovas-Massana, Campbell, Tokuyama, Vijayakumar, Geng, Muenker, Moore, Vogels, Petrone, Ott, Lu, Lu-Culligan, Klein, Venkataraman, Earnest, Simonov, Datta, Handoko, Naushad, Sewanan, Valdez, White, Lapidus, Kalinich, Jiang, Kim, Kudo, Linehan, Mao, Moriyama, Oh, Park, Silva, Song, Takahashi, Taura, Weizman, Wong, Yang, Bermejo, Odio, Omer, Dela Cruz, Farhadian, Martinello, Iwasaki, Grubaugh, & Ko, 2020) . Diagnostic potential of saliva specimens All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020 . . https://doi.org/10.1101 In the individual studies included in the quantitative synthesis, the sensitivity of the saliva test among COVID-19 infected patients ranged from 78% (Fang et al., 2020) to 100% (Azzi et al., 2020) . Pooled event rates (positive and negative test results) from saliva specimens show that the sensitivity of the saliva test was 91% (CI 80% -99%) among COVID-19 patients diagnosed in the recruitment period (Figure 2 /A). Pooled event rates from NPS specimens taken during the studies after recruitment, in parallel to saliva specimen collections indicate that the sensitivity of the NPS test in these studies was 98% (CI 89% -100%) (Figure 2 /B). Since the two confidence intervals are overlapping, it appears that the positive test proportions of the saliva and NPS tests are not very different. However, it should be emphasized that this must be confirmed in the future when data will be available for diagnostic accuracy tests utilizing more clinical studies and 2x2 contingency tables. We evaluated our pooled results for inconsistency using the I 2 test (Cumpston, Li, Page, Chandler, Welch, Higgins, & Thomas, 2019) . In the case of salivary tests we found a moderate level of heterogeneity (I 2 = 60.98%, p = 0.04) indicating the contribution of confounding factors in our analysis. On the other hand, we found a low level of heterogeneity among the NPS test results (I 2 = 46.56 %, p = 0.13). Interestingly some of the data suggest that NPS tests may occasionally be negative when the saliva test gives a positive result. In the study of Wyllie et al. the viral RNA in 8 patients was detected only in their saliva (Wyllie et al., 2020) . Azzi et al. reported that two patients showed positive All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020 . . https://doi.org/10.1101 saliva tests while their NPS tests were negative (Azzi et al., 2020) . And a case report showed that in seven samples from one individual there was no NPS positivity while the saliva specimen was positive (Deng, Hu, Yang, Zheng, Peng, Ren, Zeng, & Tian, 2020) . In a more detailed study, Bae et al. examined the difference in viral loads between the two sampling methods; the values ranged from 0.06 to 3.39 log10 units higher in the NPS specimens than in the saliva specimens (Bae et al., 2020) . One case series (Williams et al., 2020) and another case report on a 27-day-old neonate (Han, Seong, Heo, Park, Kim, Shin, Cho, Park, & Choi, 2020) also found that there were higher viral loads in the NPS specimens. On the other hand, in a sample-based study Wyllie et al. (Wyllie et al., 2020) , using 38 matched samples, detected SARS-CoV-2 in saliva but not in 8 NPS samples (21%), while detected SARS-CoV-2 in NPS and not saliva only in 3 matched samples (8%). Furthermore, they found significantly higher SARS-CoV-2 titers from saliva than NPS. Unfortunately, they did not present patient-based matched data, therefore, these observations could not be involved in our above described quantitative statistical analysis. Only two study assessed the specificity of saliva tests besides sensitivity (Williams et al., 2020) (Wyllie et al., 2020) . In one work a subset of saliva specimens from 50 patients with PCR-negative swabs was tested. SARS-CoV-2 was detected in 1/50 (2%; 95% CI 0.1%-11.5%) of these saliva samples Williams, 2020 #467}. The other tested 98 asymptomatic healthcare workers with parallel NPS and saliva tests. NPS tests turned out to be negative for all participants, while saliva tests were positive for two (Wyllie et al., 2020) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020 . . https://doi.org/10.1101 We assessed risk of bias in the six included case series (Azzi et al., 2020; Bae et al., 2020; Fang et al., 2020; Williams et al., 2020; Wyllie et al., 2020) according to the QUADAS-2 tool. Five studies (Azzi et al., 2020; Bae et al., 2020; Fang et al., 2020; Wyllie et al., 2020) had low risk of bias in selection bias. On the other hand 4 studies (Azzi et al., 2020; Bae et al., 2020; Fang et al., 2020; had high risk of bias in the index test due to the fact that the saliva tests results were interpreted with the knowledge of the results of the reference standard. Flow and timing were high or unclear in all studies, since there were no exact information regarding the time passed between specimens collection for the two tests. Applicability had low concerns in index test in four (Azzi et al., 2020; Williams et al., 2020; Wyllie et al., 2020) and unclear in two studies (Bae et al., 2020; Fang et al., 2020) . The summary of the riskof bias analysis and applicability concerns is available in Table S2 and in Table S3 . We systematically searched for clinical trial protocols that are planning to evaluate saliva specimens for COVID-19 diagnosis in 5 clinical trial registers (EU Register, ISRCTN, ANZCTR, JPRN, ClinicalTrials.gov). By using the same keywords as we applied for already completed studies, we found 18 registered clinical trials on planned or ongoing clinical studies. All of them appeared in the registry ClinicalTrials.gov (Table S2 ). Among these, 13 studies are noninterventional. These investigations primarily focus on the diagnostic values of various specimens collected from patients, including NPS, saliva, blood and others to identify the diagnostic and prognostic values of such samples in detecting and following the progression of COVID-19 disease. The additional 5 interventional studies are examining the effectiveness of several potentially beneficial compounds, such as azithromycin, lopinavir/ritonavir, beta-cyclodextrin, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020. . citrox 3 and peginterferon lambda on the outcomes of viral infection. In these studies, besides NPS specimen collections, saliva tests are also planned. In the trial protocols very little information is available about the optimization and validation of saliva collection, transportation and storage of saliva samples, nor about the viral RNA assay methods to be used for saliva samples, and the choice of appropriate internal controls in view of the scarcity of human DNA in saliva samples. In April 2020 the Food and Drug Administration (FDA) granted emergency use authorization (EUA) to Rutgers' RUCDR Infinite Biologics and its collaborators for a new specimen collection approach that utilizes saliva as the primary test biomaterial for the SARS-CoV-2 coronavirus, the first such approval granted by the federal agency (https://www.fda.gov/media/136877/download). This new saliva-based diagnostic collection method, which RUCDR has developed in partnership with Spectrum Solutions and Accurate Diagnostic Labs (ADL), claims to allow an easier and therefore broader screening of the population compared with the current method using nose and throat swabs. Another accelerated EUA for the "Curative-Korva SARS-Cov-2 Assay" was also approved to permit the testing of oral fluids, i.e. saliva (https://www.fda.gov/media/137088/download). This assay was specifically designed for use with oral fluid specimens. Nasopharyngeal swabs, oropharyngeal swabs and nasal swabs can also be used with the Curative-Korva SARS-CoV-2 Assay, but their performance with this assay has not yet been assessed (https://www.fda.gov/media/137088/download). These two saliva-based, FDAapproved assays are now in intensive use to test for COVID-19 infection, in spite of the fact that no independent, scientific analysis has not yet established their effectiveness. Our present work is All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.26.20112565 doi: medRxiv preprint the first integrative meta-analysis study to review the existing multi-study evidence for the salivabased approach. The use of saliva as a diagnostic tool for various systemic conditions is nothing new. Considerable research effort has been made in the past to seek biomarkers in saliva, since its collection is noninvasive and easy. As a result, emerging evidence indicates that whole saliva can be used to (Niedrig et al., 2018) . The presence of considerable quantities of viral RNA in the saliva of 17 SARSinfected patients has also been shown unequivocally (Wang, Chen, Liu, Chen, Chen, Yang, Chen, Yeh, Kao, Huang, Hsueh, Wang, Sheng, Fang, Hung, Hsieh, Su, Chiang, Yang, Lin, Hsieh, Hu, Chiang, Wang, Yang, & Chang, 2004) . But most studies lack any direct comparison of the sensitivity and specificity of NPS-and saliva-based assays. The one important exception is a study which compared saliva and NPS specimens for the detection of respiratory viruses by multiplex RT-PCR (Kim et al., 2017) . This study, which included results from 236 patients with 11 different viral respiratory infections, including coronaviruses, revealed no significant difference in the sensitivity and specificity of saliva-and NPS-based tests (Kim et al., 2017) . Taken together, All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.26.20112565 doi: medRxiv preprint although saliva-based diagnostics are supported by a considerable amount of evidence, routine applications are still rare because of the lack of well standardized protocols. The source of SARS-CoV-2 in saliva is unknown at present but it could come from multiple locations. One obvious source is debris from the nasopharyngeal epithelium which drains into the oral cavity . Secondly, SARS-CoV-2 may actually infect the salivary glands and the virus is then secreted into the saliva from the glands. No information is available on this. But it is of note that during the infection of rhesus macaques by the SARS coronavirus, epithelial cells lining salivary gland ducts are an early target of the virus (Liu, Wei, Alvarez, Wang, Du, Zhu, Jiang, Zhou, Lam, Zhang, Lackner, Qin, & Chen, 2011) . One consequence of this is the production of SARS-specific secretory immunoglobulin A into the saliva (Lu, Huang, Huang, Li, Zheng, Chen, Chen, Hu, & Wang, 2010) . Thirdly, SARS from blood plasma may access the mouth via the crevicular fluid, an exudate derived from periodontal tissues (Silva-Boghossian, Colombo, Tanaka, Rayo, Xiao, & Siqueira, 2013). Fourthly, infected oral mucosal endothelial cells, which show overexpression of ACE2 during SARS-CoV-2 infection may also contribute to viral load in saliva (Xu, Zhong, Deng, Peng, Dan, Zeng, Li, & Chen, 2020) . Finally, salivary cells may endocytose viruses and virus-containing exosomes from the circulation at their basolateral surface and release them into the salivary lumen by exocytosis. Such mechanisms have been revealed for other macromolecular constituents of the blood, such as DNA and RNA in exosomes (Dawes & Wong, 2019) . Any or all of these five possible sources may contribute to the appearance of SARS-CoV-2 in the saliva of COVID-19 patients. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10. 1101 In the present meta-analysis we found that the test sensitivities were 91% (CI 80% -99%) and 98% (CI 89% -100%) for saliva and for NPS samples, respectively, based the pooled event rates among COVID-19 patients. Clearly, the two confidence intervals overlap, suggesting that the outcomes of the saliva tests and NPS tests are not very different, although a tendency for NPS to be more sensitive is numerically visible. On the other hand, one study, which could not be included in the main quantitative analysis because it used a different sampling protocol, reported the opposite tendency. On a significant number of occasions (21%) they detected SARS-CoV-2 in saliva but not in matched NSP samples, whereas SARS-CoV-2 was detected in NSP and not saliva on just three occasions (8%) (Wyllie et al., 2020) . Although NPS-based SARS-CoV-2 virus detection is currently regarded as the gold standard (Lippi et al., 2020; Sullivan, Sailey, Guest, Guarner, Kelley, Siegler, Valentine-Graves, Gravens, Del Rio, & Sanchez, 2020; Zou, Ruan, Huang, Liang, Huang, Hong, Yu, Kang, Song, Xia, Guo, Song, He, Yen, Peiris, & Wu, 2020) , carefully performed future studies need to be carried out to determine both the sensitivity and specificity of the NPS and saliva tests in parallel measurements to firmly establish the relative diagnostic accuracies of these applying 2x2 contingency tables for statistical analysis. At present only two study have assessed the specificity of the saliva tests. In one of n those tests only one saliva sample was found to be positive among 50 apparently healthy individuals who were PCR-negative for the NPS test (Williams et al., 2020) . In the other work two individuals were detected positive using saliva tests among 98 participants who were negative for NPS test (Wyllie et al., 2020) . This results may reflect a real difference in the specificities of the NPS and saliva tests. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10. 1101 For optimal saliva-based testing at least three conditions have to be improved by standardization then validation (Bhattarai, Kim, & Chae, 2018) . 1) A specific saliva collection method should be selected and optimized after sytematically comparing the various methods currently used for collecting whole saliva. 2) The optimal solution for collecting, transporting and storing saliva samples should be found. 3) The RNA assay method, either RT-PCR or loop mediated isothermal amplification (LAMP) or another protocol, should also be optimized for saliva, using an appropriate internal control; this cannot be human DNA which is overwhelming in NPS but not in saliva samples (Bae et al., 2020; Fang et al., 2020; Williams et al., 2020; Wyllie et al., 2020) . . Another study (Williams et al., 2020 ) asked patients to pool saliva in their mouth prior to collection, and to spit 1-2 ml into a collection pot. The act of pooling saliva in the mouth may have stimulated additional saliva secretion, which could have diluted the specimen. In this case no transport medium was added to the specimens but, after transportation to the laboratories, liquid Amies medium was added. Wyllie et al. used a self-collection technique: patients were asked to spit repeatedly into a sterile urine cup until one third was full. This too could have diluted the sample with additional virusfree saliva. The remaining two studies did not describe the collection method at all (Bae et al., 2020; Fang et al., 2020) . Additionally, two of the studies specified that specimens were collected All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10. 1101 in early morning to avoid eating, drinking and tooth brushing Wyllie et al., 2020) .The rest of the studies did not specify the time of collection or mention any confounding factors that may have affected the sample. Other factors, such as the type of transport medium, temperature during transportation, time passed between specimen collection and RNA extraction may also affect the outcome of the tests (Bhattarai et al., 2018) . Unfortunately, there is insufficient information in these few studies to draw any conclusions about the possible effects of these confounding factors on the accuracy of saliva testing for COVID-19 diagnosis. It is likely that the simple drooling technique, with no specific target volume, will provide the greatest sensitivity if the viral RNA in whole saliva derives from sources other than the secretions of the salivary glands. Drooling is a well-established saliva collection method that is generally recommended for analytical purposes (Golatowski, Salazar, Dhople, Hammer, Kocher, Jehmlich, & Volker, 2013) . Due to its simplicity, it does not require trained personnel and can even be selfadministered. Additionally, the drooling method is much safer. Saliva is drooled directly into a container from the mouth, with no need for infected swabs to be carried in the air from patient's nostril to the container therefore reducing the risk to healthcare staff. Moreover, this saliva collecting technique is suitable to avoid the mixing of fluids from different anatomical regions as well (e.g. oropharynx), since it only collects fluid from the oral cavity (Azzi et al., 2020) . The need for reliable, non-invasive and easy-to-perform tests for COVID-19 has triggered special attention in the last few months. Between 1 January and 25 April 2020 the commencement of 18 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10. 1101 clinical trials have been reported in the ClinicalTrials.gov registry for saliva specimens (Table S2) . Among these, 13 studies are non-interventional and these focus on the diagnostic values of various specimens including saliva. Five interventional studies also plan to use saliva as a diagnostic tool together with NPS specimens, but their primary focus is on evaluating potential treatments for SARS-CoV-2 infections. Unfortunately, these registered clinical trials vary considerably in the amount of information presented about the testing methodology. Neither the non-interventional, nor the interventional protocols have clear descriptions of the collection, transportation and storage of saliva samples, and the optimization of viral RNA assays suitable for saliva specimens. Only a few of them emphasize the necessity for determining the sensitivity and specificity of the salivabased test. But hopefully, during the course of execution, such studies will yield high quality, reliable data on that matter. A limitation of the present work is the relatively small number of studies and small sample sizes available regarding this topic. Despite the large number of records found by the systematic search, only 6 could be included. Although intensive research is on progress regarding COVID-19, there are only a handful articles fulfilling our eligibility criteria. The limited number of reported data makes it difficult to perform comprehensive analyses and to thoroughly investigate the causes behind certain trends. Another issue that hinders in-depth analysis is the inhomogeneous methodologies, insufficient and deficient reporting of methods and outcome parameters. A significant limitation is the lack of data for 2x2 contingency tables since almost no specificity data are available as yet. Thus, accurate statistical methodologies (such as use of a bivariate model) specially developed for meta-analysis of diagnostic test accuracy could not be used in this work All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020. . https://doi.org/10.1101/2020.05.26.20112565 doi: medRxiv preprint All studies except two (Williams et al., 2020; Wyllie et al., 2020) , investigated the reliability of saliva test only among COVID-19 infected participants, no healthy individuals were recruited. Additionally, there are several other confounding factors which might affect the detectability of viral RNA from saliva, such as time of sample collection, method for saliva collection, virus transport medium, storage and transport temperatures, time passed between specimen collection and RNA isolation, extraction kits and PCR kits used for isolation, amplification and detection. Due to limited data the potential effect these parameters could not be investigated in our analysis. In the present meta-analysis we provide evidence that saliva tests are a promising alternative to nasopharyngeal swabs for COVID-19 diagnosis. Optimized and validated saliva assays may provide the possibility of reliable self-collection of samples for COVID-19 testing in the future. However, there are many open questions to be answered for the specificity and sensitivity of salivabased tests. Therefore, much more research is needed in order to routinely introduce determination of SARS-CoV-2 using saliva specimens in clinical practice. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020. Table S3 . Summary of risk-of-bias and applicability concerns in included studies. Table S4 . Detailed summary of risk of bias and applicability across studies. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Flow chart illustrating the selection process for identifying eligible records. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020 . . https://doi.org/10.1101 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020. . Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. 4-5 Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. 5 Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. 6 Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. 6 Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). 6 Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. 6-7 Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. 6-7 12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. 7 Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means). 7-8 Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I 2 ) for each meta-analysis. 8 29 Table S1 . Continued Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. - 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency. Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see Item 15). Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). - Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). Conclusions 26 Exposure to SARS-CoV-2 will be measured the day of delivery by RT-PCR on maternal saliva and by serology on maternal blood Description of the number of positive COVID-19 RT-PCRs in the conception products: amniotic fluid, frozen placenta fragment, frozen fetal tissue, cord blood or frozen cord fragment Blood samples, saliva collect ion, and urine collection to carry out biomarker assays and for the constitution of a biological collection. Comparison of LAMP test with reference RT-PCR on viral detection (Saliva and nasopharyngeal swab sampling) RBA-2 saliva monitoring device development. Nasopharyngeal swab and saliva sample. The comparison of the results obtained from the current testing methods will be used to calibrate machine learning algorithms of the RBA-2 1) Percentage of serological positive healthcare workers, 2) Percentage of healthcare workers with positive saliva swabs Seroconversion against SARS-CoV2 in children, Nasopharyngeal, rectal swabs, saliva and blood sampling Demographic data on participants and Proportion of participants previously hospitalized. Whole blood, peripheral blood mononuclear cells, plasma, serum and saliva. 1) Healthcare workers (n=500), 2) Nonhealthcare workers: faculty staff and students, who do not have patient contact (n=250), 3) Multigenerational household members, who test positive and negative for SARS-CoV-2 (n=540) 1) Asymptomatic high-risk subjects with known history of close personal contact with a COVID-19 positive person not tested (SARS-CoV2 status unknown), 2) Asymptomatic or mildly symptomatic subjects who are COVID-19 positive, 3) COVID-19 positive individuals retesting negative (n=60) Intervention N/A N/A N/A 1) Sensibility after 10 minutes for salivary test and after 6 hours for the nasopharyngeal swab, 2) Specificity after 10 minutes for salivary test and after 6 hours for the nasopharyngeal swab 1) Prevalence, 2) Incidence, Nasopharyngeal swab, saliva and blood sampling Determination of SARS-CoV-2 viral load and infectivity in saliva that may contribute to asymptomatic transmission. Collection of nasal and oral secretions and droplets produced by participants while they speak Secondary outcome --- (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020 . . https://doi.org/10.1101 Is there concern that the included patients do not match the review question? 6 0 0 Is there concern that the index test, its conduct, or interpretation differ from the review question? 4 0 2 DOMAIN 3: REFERENCE STANDARD Is there concern that the target condition as defined by the reference standard does not match the review question? 4 0 2 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted May 27, 2020 . . https://doi.org/10.1101 Saliva is a reliable tool to detect SARS-CoV-2 Effectiveness of Surgical and Cotton Masks in Blocking SARS-CoV-2: A Controlled Comparison in 4 Patients Compliance with Saliva Collection Protocol in Healthy Volunteers: Strategies for Managing Risk and Errors QUADAS-2. Bristol Medical School: Population Health Sciences Detecting viruses by using salivary diagnostics Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions Role of Saliva and Salivary Diagnostics in the Advancement of Oral Health Diagnosis and treatment of an acute severe pneumonia patient with COVID-19: Case report Meta-analysis in clinical trials Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients Transformations Related to the Angular and the Square Root Comparative evaluation of saliva collection methods for proteome analysis Optimizing PCR Detection of Zika Virus from Various Body Fluids Sequential analysis of viral load in a neonate and her mother infected with SARS-CoV-2 The Cochrane Collaboration's tool for assessing risk of bias in randomised trials A review of saliva: normal composition, flow, and function Saliva diagnostics -Current views and directions Stress and Salivary Glands Human saliva can be a diagnostic tool for Zika virus detection Comparison between Saliva and Nasopharyngeal Swab Specimens for Detection of Respiratory Viruses by Multiplex Reverse Transcription-PCR Coronavirus disease 2019 (COVID-19): current status and future perspectives Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19) Epithelial cells lining salivary gland ducts are early target cells of severe acute respiratory syndrome coronavirus infection in the upper respiratory tracts of rhesus macaques Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice Current developments in salivary diagnostics Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement Find the right sample: A study on the versatility of saliva and urine samples for the diagnosis of emerging viruses Quantitative proteomic analysis of gingival crevicular fluid in different periodontal conditions A Review of Salivary Diagnostics and Its Potential Implication in Detection of Covid-19 Detection of SARS-CoV-2 RNA and Antibodies in Diverse Samples: Protocol to Validate the Sufficiency of Provider-Observed, Home-Collected Blood, Saliva, and Oropharyngeal Samples Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Physiology of the salivary glands Detection of SARS-associated coronavirus in throat wash and saliva in early diagnosis QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies Saliva as a non-invasive specimen for detection of SARS-CoV-2 Probable Inference, the Law of Succession, and Statistical Inference Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance WHO Coronavirus Disease (COVID-19) Dashboard Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients